 SAN DIEGO, Sept. 27, 2021 GLOBE NEWSWIRE -- Erasca, Inc. Nasdaq: ERAS, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers, today announced that Fierce Biotech has named it as one of 2021s Fierce 15 biotechnology companies, identifying Erasca as one of the industrys most promising biotechnology companies. 